In­tec blitzed by PhI­II flop as lead pro­gram fails to beat Mer­ck­'s stan­dard com­bo for Parkin­son’s

In­tec Phar­ma’s $NTEC lead drug slammed in­to a brick wall Mon­day morn­ing. The small-cap Is­raeli biotech re­port­ed that its lead pro­gram — com­ing off a plat­form de­signed to pro­duce a safer, more ef­fec­tive oral drug for Parkin­son’s — failed the Phase III at the pri­ma­ry end­point.

Re­searchers at In­tec, which has al­ready seen its share price col­lapse over the past few months, says that its Ac­cor­dion Pill-Car­bidopa/Lev­odopa failed to prove su­pe­ri­or to Sinemet in re­duc­ing dai­ly ‘off’ time. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.